Vencel Somai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Vencel Somai has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alan J. Wright
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge, UK
16 shared publications - Kevin Michael Brindle
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
16 shared publications - Felix Kreis
Cancer Research UK Cambridge Institute Cambridge UK
15 shared publications - Friederike Hesse
Department of Radiology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt – Universität zu Berlin Berlin Germany
15 shared publications - Flaviu Bulat
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom
13 shared publications Flaviu Bulat
Cancer Research UK Cambridge Institute Cambridge UK
2 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Representative metabolite concentration maps from the central slice derived from a series of dynamic 3D 2H CSI images summed over the first 30 minutes of signal acquisition following [2,3-2H2]fumarate injection into A11 (B, C, E, and F), S2 (H, I, K, and L), and U87 (N, O, Q, and P) tumor-bearing mice. The color code represents concentration (in mmol/L) derived from the ratios of the peak intensities in the malate and fumarate maps to peak intensities in an initial HDO map and corrected for the number of 2H labels per molecule and for signal saturation. The locations of the tumors are indicated by dotted white lines determined from an underlying T2-weighted 1H image acquired concurrently using a 1H volume coil. The corresponding T2-weighted 1H images were acquired separately at 9.4 T. The tumor locations are outlined with dotted black lines. T2-weighted 1H images (A, G, and M) and the fumarate (B, H, and N) and malate (C, I, and O) concentration maps pretreatment and the corresponding T2-weighted 1H images (D, J, and P) and the fumarate (E, K, and Q) and malate (F, L, and R) concentration maps 48 hours following the last chemoradiotherapy treatment.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Representative metabolite concentration maps from the central slice derived from a series of dynamic 3D 2H CSI images summed over the first 30 minutes of signal acquisition following [2,3-2H2]fumarate injection into A11 (B, C, E, and F), S2 (H, I, K, and L), and U87 (N, O, Q, and P) tumor-bearing mice. The color code represents concentration (in mmol/L) derived from the ratios of the peak intensities in the malate and fumarate maps to peak intensities in an initial HDO map and corrected for the number of 2H labels per molecule and for signal saturation. The locations of the tumors are indicated by dotted white lines determined from an underlying T2-weighted 1H image acquired concurrently using a 1H volume coil. The corresponding T2-weighted 1H images were acquired separately at 9.4 T. The tumor locations are outlined with dotted black lines. T2-weighted 1H images (A, G, and M) and the fumarate (B, H, and N) and malate (C, I, and O) concentration maps pretreatment and the corresponding T2-weighted 1H images (D, J, and P) and the fumarate (E, K, and Q) and malate (F, L, and R) concentration maps 48 hours following the last chemoradiotherapy treatment.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
DCE MRI measurements of perfusion in A11 (n = 3; A–C), S2 (n = 3; D–F), and U87 (n = 3; G–I) tumors before and after treatment. Representative color intensity maps of mean contrast agent concentration over the first three minutes following injection in A11 (A), S2 (D), and U87 (G) tumors. The locations of the tumors are outlined by dotted white lines. Estimated contrast agent concentration in tumor tissue at the indicated times after intravenous injection before and 48 hours following the last chemoradiotherapy treatment of A11 (B), S2 (E), and U87 (H) tumors. Data are shown as mean ± SD; *, P < 0.05; ***, P < 0.001. The area under the uptake curve (AUC) showed an increase in contrast agent uptake in S2 tumors (**, P = 0.0024, paired two-tailed t test) following treatment (F), while there were no significant differences in A11 (C) and U87 (I) tumor-bearing animals. Data are presented as mean ± SD. ns, nonsignificant.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
DCE MRI measurements of perfusion in A11 (n = 3; A–C), S2 (n = 3; D–F), and U87 (n = 3; G–I) tumors before and after treatment. Representative color intensity maps of mean contrast agent concentration over the first three minutes following injection in A11 (A), S2 (D), and U87 (G) tumors. The locations of the tumors are outlined by dotted white lines. Estimated contrast agent concentration in tumor tissue at the indicated times after intravenous injection before and 48 hours following the last chemoradiotherapy treatment of A11 (B), S2 (E), and U87 (H) tumors. Data are shown as mean ± SD; *, P < 0.05; ***, P < 0.001. The area under the uptake curve (AUC) showed an increase in contrast agent uptake in S2 tumors (**, P = 0.0024, paired two-tailed t test) following treatment (F), while there were no significant differences in A11 (C) and U87 (I) tumor-bearing animals. Data are presented as mean ± SD. ns, nonsignificant.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
2H MR spectroscopy measurements of labeled fumarate, malate, and water concentrations in A11 (A–E), S2 (F–J), and U87 (K–O) tumors. Tumor spectra were acquired before and 48 hours after the last chemoradiotherapy treatment (temozolomide 100 mg/kg, 20 Gy in total, 5 Gy per fraction). Sum of 12 2H spectra recorded over 60 minutes from A11 (B and D), S2 (G and I), and U87 (L and N) tumors. Injection of [2,3-2H2]fumarate (1 g/kg) started 5 minutes after the start of acquisition of the first spectrum. The peaks were fitted individually using prior knowledge. [2,3-2H2]malate/[2,3-2H2]fumarate ratios before and 48 hours after the last chemoradiotherapy treatment of A11 (n = 3; *, P = 0.0439, paired two-tailed t test; E), S2 (n = 3; ***, P = 0.0006, paired two-tailed t test; J), and U87 (n = 3; **, P = 0.0061, paired two-tailed t test; O). Data are presented as mean ± SD.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
2H MR spectroscopy measurements of labeled fumarate, malate, and water concentrations in A11 (A–E), S2 (F–J), and U87 (K–O) tumors. Tumor spectra were acquired before and 48 hours after the last chemoradiotherapy treatment (temozolomide 100 mg/kg, 20 Gy in total, 5 Gy per fraction). Sum of 12 2H spectra recorded over 60 minutes from A11 (B and D), S2 (G and I), and U87 (L and N) tumors. Injection of [2,3-2H2]fumarate (1 g/kg) started 5 minutes after the start of acquisition of the first spectrum. The peaks were fitted individually using prior knowledge. [2,3-2H2]malate/[2,3-2H2]fumarate ratios before and 48 hours after the last chemoradiotherapy treatment of A11 (n = 3; *, P = 0.0439, paired two-tailed t test; E), S2 (n = 3; ***, P = 0.0006, paired two-tailed t test; J), and U87 (n = 3; **, P = 0.0061, paired two-tailed t test; O). Data are presented as mean ± SD.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Histologic assessment of tumor cell death 48 hours following chemoradiotherapy treatment. Representative sections of A11 (A–F), S2 (I–N), and U87 (Q–V) tumors stained with hematoxylin and eosin (H&E; A, D, I, L, Q, and T). The top panels show the whole brain section containing the tumor, and the bottom panels show a Multiplication symbol 10 magnification of part of the tumor area. The sections were co-stained for CC3 (B, E, J, M, R, and U) and TUNEL (C, F, K, N, S, and V). The percentage of CC3 (G, O, and W)- and TUNEL (H, P, and X)-positive cells pretreatment and 48 hours after the completion of treatment is shown for A11 (G and H), S2 (O and P), and U87 (W and X) tumors (n = 4 per group, drug treated and untreated). Data are shown as mean ± SD. **, P < 0.01; ***, P < 0.001.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Histologic assessment of tumor cell death 48 hours following chemoradiotherapy treatment. Representative sections of A11 (A–F), S2 (I–N), and U87 (Q–V) tumors stained with hematoxylin and eosin (H&E; A, D, I, L, Q, and T). The top panels show the whole brain section containing the tumor, and the bottom panels show a Multiplication symbol 10 magnification of part of the tumor area. The sections were co-stained for CC3 (B, E, J, M, R, and U) and TUNEL (C, F, K, N, S, and V). The percentage of CC3 (G, O, and W)- and TUNEL (H, P, and X)-positive cells pretreatment and 48 hours after the completion of treatment is shown for A11 (G and H), S2 (O and P), and U87 (W and X) tumors (n = 4 per group, drug treated and untreated). Data are shown as mean ± SD. **, P < 0.01; ***, P < 0.001.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
13C MR spectra acquired following intravenous injection of hyperpolarized [1,4-13C2,2,3-2H2]fumarate. Summed spectra showing flux of hyperpolarized 13C label between [1,4-13C2,2,3-2H2]fumarate (177.2 ppm) and [1,4-13C2,2,3-2H2]malate (182.2, 183.6 ppm) were acquired from an 8-mm tumor slice over a period of 180 seconds starting from the time of injection. Spectra were acquired from A11 (A), S2 (C), and U87 (E) tumors before and at 48 hours after the last chemo-radiotherapy session. Malate/fumarate signal ratios in A11 (n = 4, paired two-tailed t test; B), S2 (n = 4, paired two-tailed t test; D), and U87 (n = 3, paired two-tailed t test; F) tumors pre- and posttreatment. The ratios were obtained from the summed spectra. ns, nonsignificant.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
13C MR spectra acquired following intravenous injection of hyperpolarized [1,4-13C2,2,3-2H2]fumarate. Summed spectra showing flux of hyperpolarized 13C label between [1,4-13C2,2,3-2H2]fumarate (177.2 ppm) and [1,4-13C2,2,3-2H2]malate (182.2, 183.6 ppm) were acquired from an 8-mm tumor slice over a period of 180 seconds starting from the time of injection. Spectra were acquired from A11 (A), S2 (C), and U87 (E) tumors before and at 48 hours after the last chemo-radiotherapy session. Malate/fumarate signal ratios in A11 (n = 4, paired two-tailed t test; B), S2 (n = 4, paired two-tailed t test; D), and U87 (n = 3, paired two-tailed t test; F) tumors pre- and posttreatment. The ratios were obtained from the summed spectra. ns, nonsignificant.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
2H NMR measurements of labeled fumarate, malate, and water in cell culture medium. A and B, Representative 2H NMR spectra of medium from untreated S2 cells (A) and from cells 24 hours after the last chemoradiotherapy treatment (5 Gy per fraction, 15 Gy in total, and 50 μmol/L temozolomide; B), 2 hours after the addition of 5 mmol/L [2,3-2H2]fumarate. Deuterated fumarate, malate, and water concentrations in medium from untreated S2 (C), A11 (F), and U87 (I) cells and treated S2 (D), A11 (G), and U87 (J) cells at the indicated times after addition of 5 mmol/L [2,3–2H2]fumarate. Rates of labeled malate production in untreated and treated S2 (***, P = 0.0028; E), A11 (*, P = 0.0105; H), and U87 (**, P = 0.0075; K) cell suspensions (mean ± SD; n = 3 biological replicates). Cell viability was measured in control (L) and chemoradiotherapy (M)-treated S2, A11, and U87 cells at the indicated time points following collection of the media samples.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
2H NMR measurements of labeled fumarate, malate, and water in cell culture medium. A and B, Representative 2H NMR spectra of medium from untreated S2 cells (A) and from cells 24 hours after the last chemoradiotherapy treatment (5 Gy per fraction, 15 Gy in total, and 50 μmol/L temozolomide; B), 2 hours after the addition of 5 mmol/L [2,3-2H2]fumarate. Deuterated fumarate, malate, and water concentrations in medium from untreated S2 (C), A11 (F), and U87 (I) cells and treated S2 (D), A11 (G), and U87 (J) cells at the indicated times after addition of 5 mmol/L [2,3–2H2]fumarate. Rates of labeled malate production in untreated and treated S2 (***, P = 0.0028; E), A11 (*, P = 0.0105; H), and U87 (**, P = 0.0075; K) cell suspensions (mean ± SD; n = 3 biological replicates). Cell viability was measured in control (L) and chemoradiotherapy (M)-treated S2, A11, and U87 cells at the indicated time points following collection of the media samples.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Diffusion-weighted imaging of A11, S2, and U87 tumors before and after treatment. Representative T2-weighted axial slices from reference 1H images acquired at 9.4 T from an A11 tumor (A), S2 tumor (E), and U87 tumor posttreatment (I) at 7 days after treatment. The locations of the tumors are outlined by dotted black lines. Representative diffusion images, in false color, overlaid on the corresponding T2-weighted images acquired from A11 (B), S2 (F), and U87 (J) tumors before and at 48 hours and 7 days after the last chemoradiotherapy treatment. The locations of the tumors are outlined by dotted white lines. The underlying T2-weighted images acquired at 7 days after treatment are the same as those shown in A, E, and I and the underlying image shown in F at 48 hours posttreatment is the same as that shown in Fig. 3J. The 2H and diffusion-weighted images were acquired in the same imaging session as the T2-weighted images. Mean ADC measured along the slice-selective direction before and at 2 and 7 days after the last chemoradiotherapy treatment in A11 (n = 6; C), S2 (n = 6; G), and U87 (n = 6; K) tumors. Histograms of ADC values over all the animals imaged in A11 (D), S2 (H), and U87 (L) tumors. *, P < 0.05; ns, nonsignificant.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Diffusion-weighted imaging of A11, S2, and U87 tumors before and after treatment. Representative T2-weighted axial slices from reference 1H images acquired at 9.4 T from an A11 tumor (A), S2 tumor (E), and U87 tumor posttreatment (I) at 7 days after treatment. The locations of the tumors are outlined by dotted black lines. Representative diffusion images, in false color, overlaid on the corresponding T2-weighted images acquired from A11 (B), S2 (F), and U87 (J) tumors before and at 48 hours and 7 days after the last chemoradiotherapy treatment. The locations of the tumors are outlined by dotted white lines. The underlying T2-weighted images acquired at 7 days after treatment are the same as those shown in A, E, and I and the underlying image shown in F at 48 hours posttreatment is the same as that shown in Fig. 3J. The 2H and diffusion-weighted images were acquired in the same imaging session as the T2-weighted images. Mean ADC measured along the slice-selective direction before and at 2 and 7 days after the last chemoradiotherapy treatment in A11 (n = 6; C), S2 (n = 6; G), and U87 (n = 6; K) tumors. Histograms of ADC values over all the animals imaged in A11 (D), S2 (H), and U87 (L) tumors. *, P < 0.05; ns, nonsignificant.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Deuterium-labelled fumarate, malate, and water concentrations measured in the indicated tumor extracts and in extracts of the corresponding contralateral hemisphere using 2H NMR.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Deuterium-labelled fumarate, malate, and water concentrations measured in the indicated tumor extracts and in extracts of the corresponding contralateral hemisphere using 2H NMR.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Early detection of tumor cell death in glioblastoma following treatment with chemoradiation has the potential to distinguish between true disease progression and pseudoprogression. Tumor cell death can be detected noninvasively in vivo by imaging the production of [2,3-2H2]malate from [2,3-2H2]fumarate using 2H magnetic resonance (MR) spectroscopic imaging. We show here that 2H MR spectroscopy and spectroscopic imaging measurements of [2,3-2H2]fumarate metabolism can detect tumor cell death in orthotopically implanted glioblastoma models within 48 hours following the completion of chemoradiation. Following the injection of [2,3-2H2]fumarate into tumor-bearing mice, production of [2,3-2H2]malate was measured in a human cell line–derived model and in radiosensitive and radioresistant patient-derived models of glioblastoma that were treated with temozolomide followed by targeted fractionated irradiation. The increase in the [2,3-2H2]malate/[2,3-2H2]fumarate signal ratio posttreatment, which correlated with histologic assessment of cell death, was a more sensitive indicator of treatment response than diffusion-weighted and contrast agent–enhanced 1H MRI measurements, which have been used clinically to detect responses of glioblastoma to chemoradiation. Overall, early detection of glioblastoma cell death using 2H MRI of malate production from fumarate could help improve the clinical evaluation of response to chemoradiation.Significance:2H magnetic resonance imaging of labeled fumarate metabolism can detect early evidence of tumor cell death following chemoradiation, meeting a clinical need to reliably detect treatment response in glioblastoma.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Early detection of tumor cell death in glioblastoma following treatment with chemoradiation has the potential to distinguish between true disease progression and pseudoprogression. Tumor cell death can be detected noninvasively in vivo by imaging the production of [2,3-2H2]malate from [2,3-2H2]fumarate using 2H magnetic resonance (MR) spectroscopic imaging. We show here that 2H MR spectroscopy and spectroscopic imaging measurements of [2,3-2H2]fumarate metabolism can detect tumor cell death in orthotopically implanted glioblastoma models within 48 hours following the completion of chemoradiation. Following the injection of [2,3-2H2]fumarate into tumor-bearing mice, production of [2,3-2H2]malate was measured in a human cell line–derived model and in radiosensitive and radioresistant patient-derived models of glioblastoma that were treated with temozolomide followed by targeted fractionated irradiation. The increase in the [2,3-2H2]malate/[2,3-2H2]fumarate signal ratio posttreatment, which correlated with histologic assessment of cell death, was a more sensitive indicator of treatment response than diffusion-weighted and contrast agent–enhanced 1H MRI measurements, which have been used clinically to detect responses of glioblastoma to chemoradiation. Overall, early detection of glioblastoma cell death using 2H MRI of malate production from fumarate could help improve the clinical evaluation of response to chemoradiation.Significance:2H magnetic resonance imaging of labeled fumarate metabolism can detect early evidence of tumor cell death following chemoradiation, meeting a clinical need to reliably detect treatment response in glioblastoma.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Supplementary Data from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism
Supplementary Data from Imaging Glioblastoma Response to Radiotherapy Using 2H Magnetic Resonance Spectroscopy Measurements of Fumarate Metabolism